Publications

1. Carceles-Cordon M, Orme JJ, Domingo-Domenech J, Rodriguez-Bravo V. The yin and yang of chromosomal instability in prostate cancer. Nat Rev Urol. 2024 Jun; 21 (6):357-372 Epub 2024 Feb 02
   View PubMed
2. Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song WM, Fujiwara N, Li P, Mendizabal I, Petrylak DP, Kelly WK, Reddy EP, Wang L, Schiewer MJ, Lujambio A, Karnes J, Knudsen KE, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer. Cancer Discov. 2023 Sep 7 Epub 2023 Sept 07
   View PubMed
3. Dhital B, Santasusagna S, Kirthika P, Xu M, Li P, Carceles-Cordon M, Soni RK, Li Z, Hendrickson RC, Schiewer MJ, Kelly WK, Sternberg CN, Luo J, Lujambio A, Cordon-Cardo C, Alvarez-Fernandez M, Malumbres M, Huang H, Ertel A, Domingo-Domenech J, Rodriguez-Bravo V. Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. Cell Rep Med. 2023 Feb 21; 4 (2):100937 Epub 2023 Feb 13
   View PubMed
4. Mandigo AC, Yuan W, Xu K, Gallagher P, Pang A, Guan YF, Shafi AA, Thangavel C, Sheehan B, Bogdan D, Paschalis A, McCann JJ, Laufer TS, Gordon N, Vasilevskaya IA, Dylgjeri E, Chand SN, Schiewer MJ, Domingo-Domenech J, Den RB, Holst J, McCue PA, de Bono JS, McNair C, Knudsen KE. RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease. Cancer Discov. 2021 Sep; 11 (9):2334-2353 Epub 2021 Apr 20
   View PubMed
5. Sato K, Padgaonkar AA, Baker SJ, Cosenza SC, Rechkoblit O, Subbaiah DRCV, Domingo-Domenech J, Bartkowski A, Port ER, Aggarwal AK, Ramana Reddy MV, Irie HY, Reddy EP. Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. Nat Commun. 2021 Aug 3; 12 (1):4671 Epub 2021 Aug 03
   View PubMed
6. Woo J, Santasusagna S, Banks J, Pastor-Lopez S, Yadav K, Carceles-Cordon M, Dominguez-Andres A, Den RB, Languino LR, Pippa R, Lallas CD, Lu-Yao G, Kelly WK, Knudsen KE, Rodriguez-Bravo V, Tewari AK, Prats JM, Leiby BE, Gomella LG, Domingo-Domenech J. Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer. J Urol. 2020 Oct; 204 (4):691-700 Epub 2020 Apr 06
   View PubMed
7. Quaglia F, Krishn SR, Daaboul GG, Sarker S, Pippa R, Domingo-Domenech J, Kumar G, Fortina P, McCue P, Kelly WK, Beltran H, Liu Q, Languino LR. Small extracellular vesicles modulated by alphaVbeta3 integrin induce neuroendocrine differentiation in recipient cancer cells. J Extracell Vesicles. 2020 May 24; 9 (1):1761072
   View PubMed
8. Carceles-Cordon M, Kelly WK, Gomella L, Knudsen KE, Rodriguez-Bravo V, Domingo-Domenech J. Cellular rewiring in lethal prostate cancer: the architect of drug resistance. Nat Rev Urol. 2020 May; 17 (5):292-307 Epub 2020 Mar 16
   View PubMed
9. Han D, Rodriguez-Bravo V, Izadmehr S, Domingo-Domenech J, Cordon-Cardo C. Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts. J Vis Exp. 2019 Jun 13; (148) Epub 2019 June 13
   View PubMed
10. Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun. 2018 Aug 29; 9 (1):3503
    View PubMed
11. Rodriguez-Bravo V, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, Koh AP, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, Hirschfield H, Prats JM, Reddy EP, Fatatis A, Petrylak DP, Gomella L, Kelly WK, Lowe SW, Knudsen KE, Galsky MD, Cingolani G, Lujambio A, Hoshida Y, Domingo-Domenech J. Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. Cell. 2018 Aug 23; 174 (5):1200-1215.e20 Epub 2018 Aug 09
    View PubMed
12. Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV. Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol. 2018 May; 73 (5):751-759 Epub 2017 Dec 13
    View PubMed
13. Mohr L, Carceles-Cordon M, Woo J, Cordon-Cardo C, Domingo-Domenech J, Rodriguez-Bravo V. Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel. J Vis Exp. 2017 Sep 8; (127) Epub 2017 Sept 08
    View PubMed
14. Han D, Rodriguez-Bravo V, Charytonowicz E, Demicco E, Domingo-Domenech J, Maki RG, Cordon-Cardo C. Targeting sarcoma tumor-initiating cells through differentiation therapy. Stem Cell Res. 2017 May; 21:117-123 Epub 2017 Apr 13
    View PubMed
15. Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Sole M, Domingo-Domenech J, Villanueva A, Llovet JM. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut. 2017 Mar; 66 (3):530-540 Epub 2015 Dec 11
    View PubMed
16. Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J. The role of GATA2 in lethal prostate cancer aggressiveness. Nat Rev Urol. 2017 Jan; 14 (1):38-48 Epub 2016 Nov 22
    View PubMed
17. Galsky MD, Domingo-Domenech J, Sfakianos JP, Ferket BS. Definitive Management of Primary Bladder Tumors in the Context of Metastatic Disease: Who, How, When, and Why? J Clin Oncol. 2016 Oct 10; 34 (29):3495-3498
    View PubMed
18. Grau JJ, Mesia R, de la Iglesia-Vicente M, Williams ES, Taberna M, Caballero M, Larque AB, de la Oliva J, Cordon-Cardo C, Domingo-Domenech J. Enrichment of Cells with Cancer Stem Cell-Like Markers in Relapses of Chemoresistant Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma. Oncology. 2016; 90 (5):267-72 Epub 2016 Apr 15
    View PubMed
19. Williams ES, Rodriguez-Bravo V, Chippada-Venkata U, De Ia Iglesia-Vicente J, Gong Y, Galsky M, Oh W, Cordon-Cardo C, Domingo-Domenech J. Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. J Vis Exp. 2015 Oct 20; (105):53182
    View PubMed
20. Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E, Sun X, de la Iglesia-Vicente J, Lee A, Readhead B, Chen X, Galsky M, Esteve B, Petrylak DP, Dudley JT, Rabadan R, Silva JM, Hoshida Y, Lowe SW, Cordon-Cardo C, Domingo-Domenech J. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell. 2015 Feb 9; 27 (2):223-39
    View PubMed
21. Vidal SJ, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene. 2014 Sep 4; 33 (36):4451-63 Epub 2013 Oct 07
    View PubMed
22. Vidal SJ, Quinn SA, de la Iglesia-Vicente J, Bonal DM, Rodriguez-Bravo V, Firpo-Betancourt A, Cordon-Cardo C, Domingo-Domenech J. Isolation of cancer stem cells from human prostate cancer samples. J Vis Exp. 2014 Mar 14; (85)
    View PubMed
23. Jia AY, Castillo-Martin M, Domingo-Domenech J, Bonal DM, Sanchez-Carbayo M, Silva JM, Cordon-Cardo C. A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. Am J Pathol. 2013 Apr; 182 (4):1171-9 Epub 2013 Feb 12
    View PubMed
24. Galsky MD, Domingo-Domenech J. Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches. Clin Adv Hematol Oncol. 2013 Feb; 11 (2):86-92
    View PubMed
25. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, Petrylak DP, Benson MC, Silva JM, Cordon-Cardo C. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012 Sep 11; 22 (3):373-88
    View PubMed
26. Shen TH, Gladoun N, Castillo-Martin M, Bonal D, Domingo-Domenech J, Charytonowicz D, Cordon-Cardo C. A BAC-based transgenic mouse specifically expresses an inducible Cre in the urothelium. PLoS One. 2012; 7 (4):e35243 Epub 2012 Apr 09
    View PubMed
27. Wosnitzer MS, Domingo-Domenech J, Castillo-Martin M, Ritch C, Mansukhani M, Petrylack DP, Benson MC, McKiernan JM, Cordon-Cardo C. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. J Urol. 2011 Nov; 186 (5):2094-100 Epub 2011 Sept 23
    View PubMed
28. Karni-Schmidt O, Castillo-Martin M, Shen TH, Gladoun N, Domingo-Domenech J, Sanchez-Carbayo M, Li Y, Lowe S, Prives C, Cordon-Cardo C. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol. 2011 Mar; 178 (3):1350-60
    View PubMed
29. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 2010 Jul-Aug; 28 (4):401-8
    View PubMed
30. Conill C, Valduvieco I, Domingo-Domenech J, Arguis P, Vidal-Sicart S, Vilalta A. Loco-regional control after postoperative radiotherapy for patients with regional nodal metastases from melanoma. Clin Transl Oncol. 2009 Oct; 11 (10):688-93
    View PubMed
31. Domingo-Domenech J, Pippa R, Tapia M, Gascon P, Bachs O, Bosch M. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat. 2008 Nov; 112 (1):53-62 Epub 2007 Dec 06
    View PubMed
32. Grau JJ, Caballero M, Monzo M, Munoz-Garcia C, Domingo-Domenech J, Navarro A, Conill C, Campayo M, Bombi JA. Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J Surg Oncol. 2008 Aug 1; 98 (2):130-4
    View PubMed
33. Domingo-Domenech J, Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E, Alcaraz A, Codony J, Gascon P, Mellado B. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol. 2008 Feb; 19 (2):269-75 Epub 2007 Nov 12
    View PubMed
34. Caballero M, Grau JJ, Blanch JL, Domingo-Domenech J, Auge JM, Jimenez W, Bernal-Sprekelsen M. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007 Nov; 133 (11):1143-8
    View PubMed
35. Conill C, Jorcano S, Domingo-Domenech J, Marruecos J, Vilella R, Malvehy J, Puig S, Sanchez M, Gallego R, Castel T. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res. 2007 Oct; 17 (5):304-9
    View PubMed
36. Conill C, Marruecos J, Verger E, Berenguer J, Lomena F, Domingo-Domenech J, Grau JJ, Casas F. Clinical outcome in patients with intramedullary spinal cord metastases from lung cancer. Clin Transl Oncol. 2007 Mar; 9 (3):172-6
    View PubMed
37. Conill C, Gimferrer JM, Marruecos J, Domingo-Domenech J, Vilella R, Catalan M, Malvehy J, Puig S, Castel T. Clinical outcome after surgical resection of lung metastases from melanoma. Clin Transl Oncol. 2007 Jan; 9 (1):48-52
    View PubMed
38. Domingo-Domenech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascon P, Mellado B, Molina R. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol. 2007; 28 (5):264-72 Epub 2007 Oct 26
    View PubMed
39. Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campas C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res. 2006 Sep 15; 12 (18):5578-86
    View PubMed
40. Grau JJ, Palmero R, Marmol M, Domingo-Domenech J, Monzo M, Fuster J, Vidal O, Fondevila C, Garcia-Valdecasas JC. Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy. World J Surg Oncol. 2006 Aug 11; 4:53
    View PubMed
41. Conill C, Jorcano S, Domingo-Domenech J, Gallego R, Malvehy J, Puig S, Sanchez M, Vilella R, Castel T. Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases. Clin Transl Oncol. 2006 Apr; 8 (4):266-70
    View PubMed
42. Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, Albanell J. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther. 2006 Mar; 5 (3):665-75
    View PubMed
43. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, Alcover J, Campo E, Gascon P, Rovira A, Ross JS, Fernandez PL, Albanell J. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer. 2005 Nov 28; 93 (11):1285-94
    View PubMed
44. Molina R, Auge JM, Filella X, Vinolas N, Alicarte J, Domingo JM, Ballesta AM. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res. 2005 May-Jun; 25 (3A):1773-8
    View PubMed
45. Domingo-Domenech J, Molina R, Castel T, Montagut C, Puig S, Conill C, Marti R, Vera M, Auge JM, Malvehy J, Grau JJ, Gascon P, Mellado B. Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR. Oncology. 2005; 68 (4-6):341-9 Epub 2005 July 11
    View PubMed
46. Grau JJ, Domingo-Domenech J, Morente V, Pera M, Garcia-Valdecasas JC, Fuster J, Bombi A, Mellado B, Albanell J, Gascon P. Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur. Oncology. 2004; 66 (3):226-33
    View PubMed
47. Mellado B, Del Carmen Vela M, Colomer D, Gutierrez L, Castel T, Quinto L, Fontanillas M, Reguart N, Domingo-Domenech JM, Domingo-Domènech JM, Montagut C, Estape J, Gascon P. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol. 2002 Oct 1; 20 (19):4032-9
    View PubMed
48. Grau JJ, Domingo J, Blanch JL, Verger E, Castro V, Nadal A, Alos L, Estape J. Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. Oncology. 2002; 63 (4):338-45
    View PubMed